



IN THE UNITED STATES PATENT  
AND TRADEMARK OFFICE

Please do not enter

In re Application of:

Daniel A. Gamache  
David P. Bingaman  
Michael A. Kapin

Serial No.: 10/660,152 (Conf. #4949)

Filed: September 11, 2003

For: PDE IV INHIBITORS TO TREAT  
ANGIOGENESIS

**AMENDMENT and RESPONSE TO FINAL  
OFFICE ACTION DATED FEBRUARY 17, 2005**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This Amendment is filed in response to the Final Official Action mailed February 17, 2005, for which the three-month date for response is May 17, 2005.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Assistant Commissioner is authorized to deduct said fees from Alcon Laboratories Deposit Account No. 01-0682.

Reconsideration of the application is respectfully requested.

There are no **Amendments to the Specification** in this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

There are no **Amendments to the Drawings** in this paper.

**Remarks/Arguments** begin on page 3 of this paper.

Group Art Unit: 1617

Examiner: Hui, S.

Atty. Dkt. No.: 1814 US

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as "Express Mail," Mailing Label EV 676 197 905 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

17 May 2005  
Date

Barbara McKenzie  
Name


*Barbara McKenzie*

Express Mail EV 676 197 905 US

05.18.05

IFW  
AF/1617

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Total Number of Pages in This Submission

Application Number	10/660,152 (Conf #4949)
Filing Date	11 September 2003
First Named Inventor	Daniel A. GAMACHE et al.
Art Unit	1617
Examiner Name	Hui, S
Attorney Docket Number	1814 US

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Return Card	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____		
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53			
Remarks			

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	Alcon Research, Ltd.		
Signature			
Printed name	Teresa J. Schultz		
Date	Reg. No.	40,526	

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Barbara McKenzie	Date	17 May 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## II. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for treating posterior segment neovascularization which comprises, administering a pharmaceutically effective amount of a selective PDE-IV inhibitor, wherein the selective PDE-IV inhibitor is selected from the group consisting of 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-pyridazin-3-one, 3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine hydrochloride (~~V-11294A~~), 8-methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide (~~D-4418~~), cipamfylline (~~BRL 61063~~), ariflo (~~SB 207499~~), and derivatives thereof.

Claim 2 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is age-related macular degeneration.

Claim 3 (previously presented) The method of claim 2, wherein the age-related macular degeneration is exudative age-related macular degeneration.

Claim 4 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is diabetic retinopathy.

Claim 5 (previously presented) The method of claim 4, wherein the diabetic retinopathy is proliferative diabetic retinopathy.

Claim 6 (previously presented) The method of claim 1, wherein the selective PDE-IV inhibitor is administered by oral administration, transdermally, subdermally, intraperitoneally, subcutaneously, transnasally, sublingually, rectally, by topical ocular administration, intravitreally, periocularly, transclerally, retrobulbar administration, sub-tenon injection, or via an intraocular device.